

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/974,040	10/09/2001	Robert S. Kody	56685US002	7546
32692	7590 04/20/2005		EXAM	IINER
3M INNOVA PO BOX 3342	ATIVE PROPERTIES	ТНОМРЅОТ	THOMPSON, CAMIE S	
ST. PAUL, MN 55133-3427			ART UNIT	PAPER NUMBER
,			1774	

DATE MAILED: 04/20/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)		
Notice of Non-Compliant	09/974,040	KODY ET AL.		
Amendment (37 CFR 1.121)	Examiner	Art Unit		
,	Camie S. Thompson	1774		
The MAILING DATE of this communication appe		orrespondence address		
The amendment document filed on is considered non-compliant because it has failed to meet the requirements of CFR 1.121. In order for the amendment document to be compliant, correction of the following item(s) is required.				
THE FOLLOWING MARKED (X) ITEM(S) CAUSE THE A 1. Amendments to the specification: A. Amended paragraph(s) do not include B. New paragraph(s) should not be under C. Other	markings.	BE NON-COMPLIANT:		
2. Abstract:A. Not presented on a separate sheet. 37B. Other	CFR 1.72.			
 3. Amendments to the drawings: A. The drawings are not properly identified in the top margin as "Replacement Sheet," "New Sheet," or "Annotated Sheet" as required by 37 CFR 1.121(d). B. The practice of submitting proposed drawing correction has been eliminated. Replacement drawings showing amended figures, without markings, in compliance with 37 CFR 1.84 are required. C. Other 				
 ✓ A. Amendments to the claims: ✓ A. A complete listing of all of the claims is not present. ☐ B. The listing of claims does not include the text of all pending claims (including withdrawn claims) ☐ C. Each claim has not been provided with the proper status identifier, and as such, the individual status of each claim cannot be identified. Note: the status of every claim must be indicated after its claim number by using one of the following status identifiers: (Original), (Currently amended), (Canceled), (Previously presented), (New), (Not entered), (Withdrawn) and (Withdrawn-currently amended). ☐ D. The claims of this amendment paper have not been presented in ascending numerical order. ☑ E. Other: Claims 50-53 have been omitted from the amendment. Also, claim 1 is listed as presently presented; however, it has been amended from the previous amendment dated 7/9/04. 				
For further explanation of the amendment format required by 37 CFR 1.121, see MPEP § 714 and the USPTO website at http://www.uspto.gov/web/offices/pac/dapp/opla/preognotice/officeflyer.pdf .				
TIME PERIODS FOR FILING A REPLY TO THIS NOTIC	E:	•		
 Applicant is given no new time period if the non-confiled after allowance. If applicant wishes to resubmit entire corrected amendment must be resubmitted. 	the non-compliant after-final ame	endment with corrections, the		
 Applicant is given one month, or thirty (30) days, where corrected section of the non-compliant amendment amendment is one of the following: a preliminary american request for continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendment of the continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendment of the continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendment of the continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendment of the continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendment of the continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendment of the continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendment of the continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendment of the continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendment of the continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendment of the continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendment of the continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendment of the continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendment of the continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendment of the continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendment of the continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendment of the continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendment of the continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendment of the continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendment of the continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendment of the continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendment of the continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendment of the continued examination (RCE) under 37 CFR 1.103(a) or	in compliance with 37 CFR 1.12 endment, a non-final amendment CFR 1.114), a supplemental amer	1, if the non-compliant (including a submission for a adment filed within a suspension		
Extensions of time are available under 37 CFR amendment or an amendment filed in response to		amendment is a non-final		
Failure to timely respond to this notice will result Abandonment of the application if the non-confiled in response to a Quayle action; or Non-entry of the amendment if the non-complement.	mpliant amendment is a non-final	amendment or supplemental		
	SUPER	'RENA DYE VISORY PATENT EXAMINER 4		

A.U. 1714